Bondlido is a drug owned by Medrx Usa Inc. It is protected by 1 US drug patent filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 10, 2028. Details of Bondlido's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8722065 | Lidocaine Tape Preparation |
Nov, 2028
(2 years from now) | Active |
FDA has granted several exclusivities to Bondlido. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Bondlido, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Bondlido.
Exclusivity Information
Bondlido holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Bondlido's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 24, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Bondlido is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Bondlido's family patents as well as insights into
ongoing legal events
on those patents.
Bondlido's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Bondlido's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 10, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bondlido Generic API suppliers:
Lidocaine is the generic name for the brand Bondlido. 28 different companies have already filed for the generic of Bondlido, with Carlisle having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Bondlido's generic
Alternative Brands for Bondlido
There are several other brand drugs using the same active ingredient (Lidocaine) as Bondlido. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Crescita Therap |
| |
| Dentsply Pharm |
| |
| Galen Specialty |
| |
| Powder Pharms |
| |
| Scilex Pharms |
| |
| Teikoku Pharma Usa |
| |
| Thea Pharma |
| |
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lidocaine, Bondlido's active ingredient. Check the complete list of approved generic manufacturers for Bondlido
About Bondlido
Bondlido is a drug owned by Medrx Usa Inc. Bondlido uses Lidocaine as an active ingredient. Bondlido was launched by Medrx in 2025.
Approval Date:
Bondlido was approved by FDA for market use on 24 September, 2025.
Active Ingredient:
Bondlido uses Lidocaine as the active ingredient. Check out other Drugs and Companies using Lidocaine ingredient
Dosage:
Bondlido is available in system form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10% | SYSTEM | Prescription | TOPICAL |